New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates DOI
Matthias Ocker, Christian Mayr, Petra Huber‐Cantonati

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Biliary tract cancer (BTC) is a human malignancy with poor prognosis. However, significant progress has been made in understanding the molecular mechanisms of carcinogenesis, leading to development targeted therapy strategies recent years. The challenge now develop new therapeutic concepts further increase efficacy BTC treatments coming This review covers emerging and advanced approaches highly sophisticated antibody-drug conjugates (ADCs) non-ADCs, particularly relation BTC. Additionally, potential advantages disadvantages ADCs non-ADCs regarding toxicities, bioavailability, are presented discussed. Given prognosis BTCs, precision using drug - without antibodies as carriers have overcome limitations conventional chemotherapy by improving treatment specificity while reducing systemic toxicity. several open questions remain including chemical design, delivery, related diagnostic biomarkers, combinatory application strategies.

Language: Английский

New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates DOI
Matthias Ocker, Christian Mayr, Petra Huber‐Cantonati

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Biliary tract cancer (BTC) is a human malignancy with poor prognosis. However, significant progress has been made in understanding the molecular mechanisms of carcinogenesis, leading to development targeted therapy strategies recent years. The challenge now develop new therapeutic concepts further increase efficacy BTC treatments coming This review covers emerging and advanced approaches highly sophisticated antibody-drug conjugates (ADCs) non-ADCs, particularly relation BTC. Additionally, potential advantages disadvantages ADCs non-ADCs regarding toxicities, bioavailability, are presented discussed. Given prognosis BTCs, precision using drug - without antibodies as carriers have overcome limitations conventional chemotherapy by improving treatment specificity while reducing systemic toxicity. several open questions remain including chemical design, delivery, related diagnostic biomarkers, combinatory application strategies.

Language: Английский

Citations

0